CG Oncology financials
$70.52+1.31%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $4.0M | $1.1M |
| Gross profit | -$607.0K | $1.1M |
| Gross margin | −15.0% | 100.0% |
| Operating income | -$190.8M | -$114.7M |
| Net income | -$161.0M | -$88.0M |
| Net margin | −3985.0% | −7729.5% |
| Diluted EPS | $-2.08 | $-1.41 |
| EBITDA | -$189.3M | -$114.6M |
| Operating cash flow | -$132.3M | -$78.7M |
| Free cash flow | -$132.5M | -$78.9M |
| Diluted shares | 77.3M | 62.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $32.5M | $257.1M |
| Short-term investments | $709.7M | $484.9M |
| Total debt | $3.0M | $0.00 |
| Total assets | $791.6M | $754.8M |
| Total liabilities | $39.0M | $21.4M |
| Shareholders' equity | $752.6M | $733.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology